AstraZeneca · conference-presentation
AstraZeneca | Investor Event Presentation Deck | 55 slides
55 pages · 3 arc beats · 1 loops
AstraZeneca | Investor Event Presentation Deck | 55 slides
AstraZeneca · 2024-09 arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
12468101214161820222426283032343638404244464850525455
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 9 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits — 0/1 slides
100% 1/1 slides — 0/1 slides
100% 1/1 slides 100% 1/1 slides Agitate (Make it worse) 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits — 0/3 slides
66.7% 2/3 slides 66.7% 2/3 slides 100% 3/3 slides 100% 3/3 slides Solution (Provide relief) 5 slides 100% 5/5 slides 100% 5/5 slides · 20 hits — 0/5 slides
80% 4/5 slides · 6 hits 40% 2/5 slides 100% 5/5 slides 100% 5/5 slides Slide inventory
55 every slide · same image gating as the playbook
05
Includes AstraZeneca branding and a molecular visualization background.front_matter
06
Uses a waterfall-bridge style to illustrate revenue growth drivers and headwinds.quantify_opportunity
07
The slide uses a structured grid to map high-level strategic goals to specific clinical assets.present_solution
08
The slide uses a three-pillar framework to describe the company's strategic approach to oncology.present_framework
09
The slide uses a grid of cards to present clinical trial names, associated drugs, and key outcomes.summarize
11
The slide highlights high-impact clinical trial results presented at two major oncology conferences.summarize
12
The slide uses a three-row structure to categorize clinical and technological progress.summarize
14
The slide uses a process diagram to illustrate the mechanism of action and a benefit-chain to explain the clinical advantages of the linker design.present_solution
15
The slide uses a checkmark/cross comparison matrix to demonstrate the superiority of QCS over IHC.compare_peers
16
The slide uses a process flow diagram to explain the computational pathology workflow.present_framework
17
Includes a Kaplan-Meier survival curve, a bar chart of prevalence by histology, and a Venn-style diagram illustrating the patient population selection process.analyze_data
18
Includes two Kaplan-Meier plots with embedded summary tables for Non-squamous/non-AGA BEP and Overall BEP populations.analyze_data
19
The slide uses a matrix-like layout to map clinical trials to patient segments. The right-hand side provides a strategic summary of the trial program's design ppresent_framework
20
Illustrates the transition from external lab processing to in-house diagnostic capabilities.plan_implementation
22
Includes references to clinical trials (CheckMate 274, AMBASSADOR, NIAGARA) and drug (Imfinzi).diagnose_problem
23
Clinical trial design flow chart.present_framework
24
The slide outlines a hierarchical testing strategy with alpha-exhaustive recycling and gatekeeping.present_framework
25
The slide presents clinical trial baseline data for two study arms.summarize
26
Includes a table of clinical trial statistics (events, median EFS, HR, P-value) and a risk table.analyze_data
27
Forest plot showing hazard ratios for Imfinzi vs comparator across clinical subgroups.analyze_data
28
Includes 'No. of patients at risk' table and statistical summary table.analyze_data
29
Forest plot showing hazard ratios with 95% confidence intervals for multiple clinical subgroups.analyze_data
30
The table compares safety data across various categories of adverse events, including grade 3/4, serious AEs, and treatment-related outcomes.analyze_data
31
The chart uses a diverging bar structure to compare two treatment arms side-by-side.analyze_data
Open slide detailLoop · Cost Of Inaction
33
Includes corporate branding and a biological illustration of an antibody-drug conjugate or similar protein structure.front_matter
Open slide detailLoop · Cost Of Inaction
34
The slide uses a market segmentation approach to map clinical trials (NIAGARA, POTOMAC, VOLGA, NILE) to patient populations (NMIBC, MIBC, 1L mUC).diagnose_problem
Open slide detailLoop · Cost Of Inaction
35
The slide uses a three-row structure to categorize reasons for confidence: clinical evidence, safety/experience, and implementation/stakeholder alignment.summarize
Open slide detailLoop · Cost Of Inaction
38
The chart is a stacked area chart showing market growth by target segment (HER2, TROP2, Nectin4, etc.).size_opportunity
39
The slide uses a horizontal bar chart to represent clinical development stages for six different ADC assets.present_solution
40
The slide compares plasma concentration over time for two different ADCs, showing the stability of the ADC vs the mAb and the low levels of free payload.summarize
41
Waterfall plot shows best change in target lesion size; includes CA-125 response markers.summarize
42
Waterfall plot shows RECIST v1.1 response criteria. Includes legend for dose levels and callout boxes for clinical outcomes.analyze_data
43
The slide features a stylized 3D rendering of a bispecific antibody molecule.transition
44
The slide highlights the structural design (knob-into-hole) and clinical development pipeline for two specific IO assets.present_solution
45
WCLC conference presentation slide. Includes waterfall plot and summary table of ORR and treatment continuation.summarize
46
Spider plot (swimmer plot variant) showing individual patient response trajectories.analyze_data
47
Waterfall plot shows tumor shrinkage; includes key clinical metrics (ORR, mPFS) and safety/future trial status.summarize
49
The chart uses a bridge/waterfall structure to show revenue growth drivers.plan_implementation
50
The slide uses a grid-based layout to organize events by year, with checkmarks indicating completed or high-priority milestones.plan_implementation
51
The slide lists six key executives with their titles and headshots.introduce_nominees
53
The slide uses a grid layout to categorize clinical trials by disease stage and patient population, highlighting established standards of care (SoC) with hatcheanalyze_data
54
The slide uses a matrix structure to categorize clinical trials (e.g., DESTINY-Breast, TROPION-Breast, CAPItello) by patient population and treatment line.analyze_data